Trial · NCT04667104
Participant flow27
How many started, completed or left each group, period by period.
1 to 20 of 27
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| TP 1: From Week 1 to Week 12 | STARTED | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | 48 | |
| TP 1: From Week 1 to Week 12 | STARTED | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 0 | |
| TP 1: From Week 1 to Week 12 | STARTED | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | 0 | |
| TP 1: From Week 1 to Week 12 | COMPLETED | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | 48 | |
| TP 1: From Week 1 to Week 12 | COMPLETED | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 0 | |
| TP 1: From Week 1 to Week 12 | COMPLETED | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | 0 | |
| TP 1: From Week 1 to Week 12 | NOT COMPLETED | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | 0 | |
| TP 1: From Week 1 to Week 12 | NOT COMPLETED | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 0 | |
| TP 1: From Week 1 to Week 12 | NOT COMPLETED | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | 0 | |
| TP 2: From Week 12 to Week 24 | STARTED | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | 0 | |
| TP 2: From Week 12 to Week 24 | STARTED | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 48 | |
| TP 2: From Week 12 to Week 24 | STARTED | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | 0 | |
| TP 2: From Week 12 to Week 24 | COMPLETED | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | 0 | |
| TP 2: From Week 12 to Week 24 | COMPLETED | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 48 | |
| TP 2: From Week 12 to Week 24 | COMPLETED | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | 0 | |
| TP 2: From Week 12 to Week 24 | NOT COMPLETED | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | 0 | |
| TP 2: From Week 12 to Week 24 | NOT COMPLETED | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 0 | |
| TP 2: From Week 12 to Week 24 | NOT COMPLETED | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | 0 | |
| FU:Week 24 to FU Week 48 (i.e.Week 72.4) | STARTED | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | 0 | |
| FU:Week 24 to FU Week 48 (i.e.Week 72.4) | STARTED | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04667104/flow